Pharmaceutical companies Pfizer and Bioentech announced Thursday morning that real-world evidence from the Israeli Ministry of Health shows that “dramatically” fewer Covid-19 cases and deaths have occurred among Israelis who have been fully vaccinated by Pfizer / Bioentech. Comparison of those who have not been vaccinated.
The latest analysis by the Israeli Ministry of Health is based on data collected between January 17 and March 6. During that time, the Pfizer / Bioentech vaccine was the only Covid-19 vaccine available in the country and the first known coronavirus variant B.1.1.7 was prevalent in the United Kingdom.
According to the announcement by Pfizer and Bioentech, the latest analysis from the Israeli Ministry of Health showed that two weeks after the second dose, the effectiveness of the vaccine to prevent pathological disease, hospitalization and death was at least 97%. The analysis also found that the vaccine’s effectiveness in preventing asymptomatic covid-19 was 94%, where the infection showed no symptoms.
“We are strongly encouraged that real-world efficacy data from Israel confirming the high efficacy demonstrated in our Phase 3 clinical trials and demonstrating the significant effect of the vaccine in preventing serious disease and death due to Covid-19,” said Lewis Joder, Pfizer. Senior Vice President and Chief Medical Officer of Vaccines, said in the announcement.
“The findings that suggest that the vaccine also provides protection against asymptomatic SARS-CV-2 infections are particularly significant because we prevent the spread of the virus worldwide,” Joder said.
SARS-CoV-2 is the name of the virus that causes Covid-19.
The announcement comes about two weeks after a study published in the New England Journal of Medicine – which means people infected with comovirus and sick – saw a 94% reduction in people who received two doses. The vaccine. Even before the second dose, the effectiveness of the vaccine reached 60%.
“This clearly demonstrates the power of the COVID-19 vaccine to fight the virus and encourages us to move more vigorously with the vaccination campaign. “And social work in the distant future,” the Israeli Ministry of Health, Yeshkal Levy, said in the announcement.
“When we started our development in January last year, our goal was to make a difference for people worldwide and help end this epidemic,” said Dr. Ugur Sahin, co-founder and CEO of Bioentech. “One year after the epidemic was declared by the WHO, we now see that we are on the right track to achieving our goals.”
Pfizer CEO Albert Borla said Israeli data showing the Pfizer / bioentech vaccine prevents asymptomatic infections and a year after the death epidemic was declared is a message of hope.
“This is a great opportunity, I think we have a message of hope on this day, the first anniversary of the declaration of the epidemic,” Borla told Mag Tyrell on CNBC’s Squawk Bux.
Borla explained that the data comes from a country where more than 55% of the total population has been vaccinated.
The effectiveness so far in Israel is 97%, stating that “all three measures in the real-world effectiveness with millions of people vaccinated, mild disease, hospitalization and mortality are north of %%.”
He said that, perhaps most importantly, it is 94% effective against asymptomatic transmissions.
“Because asymptomatic carriers, asymptomatic patients are the ones who are primarily spreading the disease,” Bourla said.
“This is the first time we are coming up with a confirmation of a real world evidence study of that magnitude.”
.
